Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD
Age-related macular degeneration (AMD) is the most common cause of visual loss in older populations ...
Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease. It i...
Age-related macular degeneration (AMD) is the leading cause of severe, irreversible central vision l...
PurposeAlthough important progress has been made in understanding age-related macular degeneration (...
Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Opht...
Age-related macular degeneration(AMD)is one of the important eye diseases of the WHO present three b...
Copyright © 2015 Makoto Ishikawa et al. This is an open access article distributed under the Creativ...
Copyright © 2013 Mostafa Hanout et al.This is an open access article distributed under theCreative C...
Introduction: The clinical development of anti-VEGF therapies for the treatment of exudative age-rel...
Background: Age-related macular degeneration (AMD) is a leading cause of blind registration in Weste...
Introduction: In developed countries, neovascular age-related macular degeneration (AMD) is the lead...
Introduction and purpose: Age-related macular degeneration (AMD) is a major cause of blindness in hi...
Age-related macular degeneration (AMD) is an eye disease typically associated with the aging and ca...
PurposeThis essay reviews the experimental treatments and new imaging modalities that are currently ...
This review article summarizes the most recent clinical trials for dry age-related macular degenerat...
Age-related macular degeneration (AMD) is the most common cause of visual loss in older populations ...
Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease. It i...
Age-related macular degeneration (AMD) is the leading cause of severe, irreversible central vision l...
PurposeAlthough important progress has been made in understanding age-related macular degeneration (...
Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Opht...
Age-related macular degeneration(AMD)is one of the important eye diseases of the WHO present three b...
Copyright © 2015 Makoto Ishikawa et al. This is an open access article distributed under the Creativ...
Copyright © 2013 Mostafa Hanout et al.This is an open access article distributed under theCreative C...
Introduction: The clinical development of anti-VEGF therapies for the treatment of exudative age-rel...
Background: Age-related macular degeneration (AMD) is a leading cause of blind registration in Weste...
Introduction: In developed countries, neovascular age-related macular degeneration (AMD) is the lead...
Introduction and purpose: Age-related macular degeneration (AMD) is a major cause of blindness in hi...
Age-related macular degeneration (AMD) is an eye disease typically associated with the aging and ca...
PurposeThis essay reviews the experimental treatments and new imaging modalities that are currently ...
This review article summarizes the most recent clinical trials for dry age-related macular degenerat...
Age-related macular degeneration (AMD) is the most common cause of visual loss in older populations ...
Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease. It i...
Age-related macular degeneration (AMD) is the leading cause of severe, irreversible central vision l...